Portfolio Highlights

Pappas Ventures News

• A Path Forward for the FDA
  February 1, 2012
• Eric Linsley speaks on CED Life Science
  January 31, 2012

In the Spotlight

• Michael Grey, Venture Partner
  Earlier this year Mike spearheaded the creation of our new portfolio company Lumena Pharmaceuticals, for which he serves as CEO. Mike has been a member of our SAB and is currently a Venture Partner.

• Syndax Pharmaceuticals
  The recently announced phase 2 results show median survival advantage of seven months for exemestane plus entinostat treated women with advanced breast cancer.